Disability-adjusted Life Years for respiratory syncytial virus in children under 2 years

Abstract

BACKGROUND : Respiratory syncytial virus infection is the leading cause of bronchiolitis in Colombia. There is growing evidence about the impact of Respiratory syncytial virus on society in terms of years of life lost due to this condition. The objective of the present study is to determine the Disability-Adjusted Life Years for respiratory syncytial virus in children under 2 years in Colombia METHODS : Data from the national epidemiological surveillance system were used to estimate DALYs, calculated from the sum of years of life lost and years lived with disability due to RSV infection in Colombia. A bootstrapped method with 10000 iterations was used to estimate each statistical parameter using the package DALY calculator in R. RESULTS : In 2019, 260 873 years of life (CI95% 208 180- 347 023) were lost due to RSV bronchiolitis in Colombian children under 2 years. The estimated rate was 20 DALYs / 1000 person-year (95% CI 16 – 27). CONCLUSION : This is the first report estimating the impact of RSV bronchiolitis morbidity and mortality in Colombia. The findings of the present study suggest that the actual burden and cost of bronchiolitis due to RSV is high. Prevention strategies, such as RSV vaccination, to reduce morbidity associated with RSV infection should be encouraged in our country.

Budget Impact Analysis of Surfactant Therapy for Bronchiolitis In Critically Ill Infants: The Colombian National Health System Perspective

“…Our study are in line with this conclusion being the rst economic evaluation published to this respect. The evaluation of the impact of drug with new indications represent a key issue in health policy development Previous publications have shown that bronchiolitis has a relevant impact on healthcare resources consumption and related expenditures, especially in severe cases, and any intervention that reduces the burden of disease and costs is highly appropriate to any health system (3,4,9,17). Surfactant is the therapy with the highest level of expectations due to a positive effect in PICU length of stay, but still a few evidence in endpoints such as mortality.…”